Clinical Trial: Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07179380) titled 'Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)' on Sept. 10.

Brief Summary: The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Pulmonary Hypertension Interstitial Lung Disease

Intervention: DRUG: Treprostinil Palmitil Inhalation Powder

Oral inhalation using a capsule-based dry powder inhaler device.

DRUG: Placebo

Oral inhala...